This inventor holds 3 USPTO granted patents. Top assignee: Entos Pharmaceuticals Inc.. Active years: 2019-2025.
Company Filing History:
Years Active: 2019-2025
Title: Rae-Lynn Nesbitt: Innovator in Membrane Fusion Technologies
Introduction
Rae-Lynn Nesbitt is a prominent inventor based in Port Stanley, Canada. She has made significant contributions to the field of biotechnology, particularly in the development of recombinant polypeptides for membrane fusion. With a total of 3 patents to her name, her work is paving the way for advancements in drug delivery systems and cellular interactions.
Latest Patents
One of Rae-Lynn's latest patents focuses on recombinant polypeptides designed to facilitate membrane fusion. This innovative polypeptide has a sequence with at least 80% identity to the ectodomain of the p14 fusion-associated small transmembrane (FAST) protein. It also includes a functional myristoylation motif, a transmembrane domain from a FAST protein, and a sequence with at least 80% identity to the endodomain of the p15 FAST protein. The patent outlines the potential for adding a targeting ligand to enhance selective fusion. Furthermore, the recombinant polypeptide can be incorporated into the membrane of liposomes to aid in the delivery of bioactive compounds, such as siRNA. Alternatively, it can be mixed with a lipid carrier and introduced to cultured cells to induce cell-cell fusion and heterokaryon formation.
Career Highlights
Rae-Lynn Nesbitt is currently employed at Entos Pharmaceuticals Inc., where she continues to innovate in the field of biotechnology. Her work is characterized by a strong focus on practical applications of her inventions, particularly in therapeutic contexts.
Collaborations
Throughout her career, Rae-Lynn has collaborated with notable colleagues, including Roy Duncan and John Lewis. These partnerships have contributed to the advancement of her research and the successful development of her patented technologies.
Conclusion
Rae-Lynn Nesbitt is a trailblazer in the field of membrane fusion technologies, with her innovative patents and collaborative efforts driving significant advancements in biotechnology. Her work continues to have a lasting impact on drug delivery systems and cellular interactions.